Teva Pharmaceutical Industries (TEVA) Total Liabilities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Total Liabilities for 18 consecutive years, with $32.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 3.59% year-over-year to $32.1 billion; the trailing twelve-month figure through Jun 2026 stood at $32.1 billion (down 3.59% YoY), and the FY2025 full-year result was $32.8 billion, down 2.3% from the prior year.
• Total Liabilities climbed to $32.1 billion in Q2 2026 per TEVA's latest filing, from $31.8 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $36.8 billion in Q1 2022 and bottomed at $31.8 billion in Q1 2026.
• Historically, Total Liabilities has averaged $34.3 billion across 5 years, with a median of $34.8 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities advanced 1.92% in 2024, then retreated 8.75% in 2025.
• Over 5 years, Total Liabilities stood at $35.4 billion in 2022, then decreased by 0.17% to $35.4 billion in 2023, then retreated by 4.94% to $33.6 billion in 2024, then dropped by 2.3% to $32.8 billion in 2025, then slipped by 2.24% to $32.1 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $32.1 billion, $31.8 billion, and $32.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.